Thermo Fisher Scientific 株価情報 (NYSE: TMO)

最新ニュース Thermo Fisher Scientific (NYSE:TMO) 株価情報

Thermo Fisher Scientific

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific Inc

TomTom NV

TOMOE ENGINEERING CO by Tomoe Engineering Co. Ltd.

Trimol Group Inc

Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), the world leader in serving science, today announced that its Board of Directors has authorized the repurchase of $4 billion of shares of its common stock in the open market or in negotiated transactions. The authorization has no expiration date. This replaces the company's existing repurchase authorization, of which $1 billion was remaining.

News

Buybacks

Thermo Fisher Scientific Authorizes $4B Of Share Repurchases; Replaces The Company's Existing Repurchase Authorization, Of Which $1B Was Remaining

Financial giants have made a conspicuous bullish move on Thermo Fisher Scientific. Our analysis of options history for Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) revealed 12 unusual trades.
Delving into the details, we found 41% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $638,204, and 6 were calls, valued at $1,331,814.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $520.0 to $610.0 for Thermo Fisher Scientific during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Thermo Fisher Scientific's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Thermo Fisher Scientific's whale activity within a strike price range from $520.0 to $610.0 in the last 30 days. 
<h3>Thermo Fisher Scientific Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731614512_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$98.2</td>
<td>$98.0</td>
<td>$98.0</td>
<td>$540.00</td>
<td>$588.0K</td>
<td align="right">3</td>
<td align="right">101</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$77.1</td>
<td>$71.2</td>
<td>$77.1</td>
<td>$610.00</td>
<td>$308.4K</td>
<td align="right">40</td>
<td align="right">52</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$98.4</td>
<td>$91.0</td>
<td>$98.4</td>
<td>$540.00</td>
<td>$196.8K</td>
<td align="right">3</td>
<td align="right">40</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$98.1</td>
<td>$98.1</td>
<td>$98.1</td>
<td>$540.00</td>
<td>$196.2K</td>
<td align="right">3</td>
<td align="right">135</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$98.4</td>
<td>$98.5</td>
<td>$98.5</td>
<td>$540.00</td>
<td>$187.1K</td>
<td align="right">3</td>
<td align="right">19</td>
</tr>
</tbody>
</table>

<h3>About Thermo Fisher Scientific</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).
Following our analysis of the options activities associated with Thermo Fisher Scientific, we pivot to a closer look at the company's own performance.
<h3>Thermo Fisher Scientific's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,042,301, with TMO's price down by -0.94%, positioned at $536.79.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 76 days.</li>
</ul>
<h3>Expert Opinions on Thermo Fisher Scientific</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $647.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Stifel persists with their Buy rating on Thermo Fisher Scientific, maintaining a target price of $665. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Thermo Fisher Scientific with a target price of $718. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Thermo Fisher Scientific, targeting a price of $610. 
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Thermo Fisher Scientific with a target price of $620. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for Thermo Fisher Scientific, targeting a price of $622. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Thermo Fisher Scientific, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Check Out What Whales Are Doing With TMO

With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) reported its third quarter revenue grew&nbsp;14% on an operational basis&nbsp;due to approved cancer products from Seagen it acquired last December. On the other hand, Moderna Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) posted a surprise profit and higher than expected revenue following the launch of its updated Covid-19 vaccine earlier this year as focused on slashing costs. But, even with Covid-19 still lingering in the air, Moderna has also focused on harnessing the power of mRNA to make biotech history by revolutionizing cancer treatment. However, there is also a significant advancement in early screening and even possible prevention when it comes to the cancer front. For example, their much smaller peer,&nbsp;Mainz Biomed (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mynz#NASDAQ">MYNZ</a>) just announced a new collaboration agreement aimed at developing and potentially commercializing its next generation colorectal cancer screening product.
Mainz Biomed&rsquo;s next generation CRC screening product is coming to redefine standards.
Mainz Biomed is a molecular genetics diagnostic company specialized in the early detection of cancer. This week, it announced it entered into a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tmo#NYSE">TMO</a>), through its subsidiary Life Technologies Corporation, a leading provider of life sciences solutions and services.
With the power of Thermo Fisher&rsquo;s powerful technologies, instrumentation and information translation systems, Mainz Biomed will be empowered to develop the proprietary assays for its mRNA-based next-generation CRC screening tests which are raising the bar when it comes to early cancer detection. With U.S. and European clinical trials of its flagship non-invasive test, Mainz Biomed promises to redefine standards in cancer screening. With ColoAlert, Mainz Biomed not only offers the early detection of colorectal cancer but also detects advanced adenomas which are a known cancer precursor, therefore, opening the doors its peers didn&rsquo;t dare to tackle, the ones of cancer prevention.&nbsp;
Pfizer topped estimates and hiked its full year guidance.&nbsp;
Cancer drugs brought in $854 million to Pfizer&rsquo;s revenue table, including $409 million from a targeted treatment for bladder cancer called Padcev and $268 million from lymphoma-targeting Adectris. Good results provided some much-needed good news for Pfizer CEO Albert Bourla, who is facing new pressure from activist investor Starboard Value.
For the third quarter, Pfizer reported overall revenue of &nbsp;$17.7 billion.
Moderna continues to focus on developing cancer treatment along with lowering costs.
Back in September, Moderna revealed its plan to cut its research and development budget by $1.1 billion over the next three years while it aims to get FDA approval for 10 products like cancer treatments and vaccines. During the latest earnings call, Moderna CEO St&eacute;phane Bancel was pleased with the cost efficiency achieved during the quarter, with the progress being even better than planned. For the third quarter, Moderna reported revenue of&nbsp;$1.86 billion, smashing LSEG&rsquo;s consensus estimate of $1.25 billion. While Pfizer already counts on oncology for boosting sales, Moderna&rsquo;s sales are still made by the Covid shot, along with RSV one that brought&nbsp;&nbsp;$10 million in U.S. sales after gaining approval in May. However, with 45 products in development powered by its messenger RNA platform, Moderna expects to bring 10 of them to the market over the next three years.
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Penny Stocks

General

MRNA

MYNZ

The Oncology Bet Is Already Paying Off For Pfizer

Mainz Biomed Partners With Thermo Fisher Scientific To Develop Next-Gen Colorectal Cancer Screening Product, Focusing On Early Detection And Advanced Adenoma Identification

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 15 years by 6.7% on an annualized basis producing an average annual return of 18.36%. Currently, Thermo Fisher Scientific has a market capitalization of $212.03 billion. 
Buying $100 In TMO: If an investor had bought $100 of TMO stock 15 years ago, it would be worth $1,242.44 today based on a price of $555.47 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730836834_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth Today

Investors with a lot of money to spend have taken a bullish stance on Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with TMO, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 14 options trades for Thermo Fisher Scientific.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 21%, bearish.
Out of all of the options we uncovered, 13 are puts, for a total amount of $444,315, and there was 1 call, for a total amount of $35,800.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $520.0 and $570.0 for Thermo Fisher Scientific, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Thermo Fisher Scientific's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Thermo Fisher Scientific's whale trades within a strike price range from $520.0 to $570.0 in the last 30 days. 
<h3>Thermo Fisher Scientific Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730139332_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.9</td>
<td>$8.3</td>
<td>$8.05</td>
<td>$530.00</td>
<td>$72.4K</td>
<td style="text-align: right;">201</td>
<td style="text-align: right;">121</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.2</td>
<td>$8.0</td>
<td>$8.13</td>
<td>$530.00</td>
<td>$49.5K</td>
<td style="text-align: right;">201</td>
<td style="text-align: right;">264</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.2</td>
<td>$8.1</td>
<td>$8.08</td>
<td>$530.00</td>
<td>$41.2K</td>
<td style="text-align: right;">201</td>
<td style="text-align: right;">398</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$72.8</td>
<td>$70.4</td>
<td>$71.6</td>
<td>$550.00</td>
<td>$35.8K</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/08/24</td>
<td>$11.6</td>
<td>$9.5</td>
<td>$10.48</td>
<td>$560.00</td>
<td>$31.5K</td>
<td style="text-align: right;">79</td>
<td style="text-align: right;">30</td>
</tr>
</tbody>
</table>

<h3>About Thermo Fisher Scientific</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
In light of the recent options history for Thermo Fisher Scientific, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Thermo Fisher Scientific's Current Market Status</h3>
<ul>
<li>Trading volume stands at 472,526, with TMO's price down by -0.34%, positioned at $552.47.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 93 days.</li>
</ul>
<h3>Professional Analyst Ratings for Thermo Fisher Scientific</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $637.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Thermo Fisher Scientific, which currently sits at a price target of $610. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for Thermo Fisher Scientific, targeting a price of $630. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Thermo Fisher Scientific with a target price of $660. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Thermo Fisher Scientific, which currently sits at a price target of $665. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for Thermo Fisher Scientific, targeting a price of $622. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Thermo Fisher Scientific, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Market Whales and Their Recent Bets on TMO Options

Bernstein analyst Eve Burstein maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Market Perform and lowers the price target from $625 to $620.

Price Target

Analyst Ratings

Bernstein Maintains Market Perform on Thermo Fisher Scientific, Lowers Price Target to $620

RBC Capital analyst Conor McNamara maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and lowers the price target from $767 to $718.

RBC Capital Maintains Outperform on Thermo Fisher Scientific, Lowers Price Target to $718

WIIM

Thermo Fisher Scientific shares are trading lower after multiple firms lowered their respective price targets on the stock.

Stifel analyst Daniel Arias maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy and lowers the price target from $680 to $665.

Stifel Maintains Buy on Thermo Fisher Scientific, Lowers Price Target to $665

Evercore ISI Group analyst Vijay Kumar maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and lowers the price target from $630 to $620.

Evercore ISI Group Maintains Outperform on Thermo Fisher Scientific, Lowers Price Target to $620

Wells Fargo analyst Brandon Couillard maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Overweight and lowers the price target from $670 to $660.

Wells Fargo Maintains Overweight on Thermo Fisher Scientific, Lowers Price Target to $660

Baird analyst Catherine Schulte maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and lowers the price target from $632 to $622.

Baird Maintains Outperform on Thermo Fisher Scientific, Lowers Price Target to $622

STOCK RISES ALMOST 2%
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="806" height="789" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/23201141/Screen-Shot-2024-10-23-at-4.12.36-PM.png" alt="" class="wp-image-2678" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/23201141/Screen-Shot-2024-10-23-at-4.12.36-PM.png 806w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/23201141/Screen-Shot-2024-10-23-at-4.12.36-PM-300x294.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/23201141/Screen-Shot-2024-10-23-at-4.12.36-PM-768x752.png 768w" sizes="(max-width: 806px) 100vw, 806px" /></figure>
Thermo Fisher Scientific, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:33 AM on October 23rd , a significant trading signal occurred for Thermo Fisher Scientific, Inc. as it demonstrated a Power Inflow at a price of $567.46. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in TMO&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in TMO&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and studies both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted by active traders as a bullish signal.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for TMO, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data are brought to you by Benzinga APIs</a> and include firms, like <a href="https://finitusa.com/en/">Finit USA</a>, responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $567.46. The returns on the High price ($577.02) and Close price ($576.57) after the Power Inflow were respectively 1.7% and 1.6%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case, the high of the day and close were very close but that is not always the case
Past Performance is Not Indicative of Future Results

Signals

Tradepulse Power Inflow Alert: Thermo Fisher Scientific Inc. Climbs Over 9 Points On Session After Alert

Wall Street is on track for its third consecutive day of losses as investors grow cautious about risky assets, awaiting more clarity on U.S. fiscal and monetary policies and scrutinizing the latest <a href="https://www.benzinga.com/earnings">batch of corporate earnings.</a>
Both equities and commodities took a hit on Wednesday, while the U.S. dollar gained strength, attracting investor flows as traders moved to safer cash positions.
The U.S. dollar index, as tracked by the the&nbsp;Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), rose 0.5%, reaching levels last seen in late July. 
At midday in New York, the S&amp;P 500 was down 0.7%, attempting to hold support around the 5,800-point level. The Dow Jones also dropped 0.7%, and tech stocks, along with small caps, fared worse, sliding by 0.9%.
On the data front, mortgage applications declined for the fourth straight week, reflecting continued pressure <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41488744/mortgage-applications-fall-for-fourth-straight-week-as-high-rates-squeeze-homebuy">from elevated borrowing costs.</a>
Existing home sales fell by 1% in September to a seasonally adjusted annualized rate of 3.84 million, the lowest level since October 2010. This follows an upwardly revised 3.88 million in August and missed forecasts of 3.9 million.
Despite weak housing data, real estate stocks showed surprising resilience. The Vanguard Real Estate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNQ#NYSE">VNQ</a>) and the SPDR Homebuilders ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XHB#NYSE">XHB</a>) moved higher after two straight sessions of losses.
Gold prices, as tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), fell more than 1%, pulling mining stocks down with it. Silver plummeted over 3%, retreating from 12-year highs reached on Tuesday.
Oil prices slipped by 1%, while Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) tumbled 2%. 
<h1 class="wp-block-heading">Wednesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,815.02</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,625.59</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,213.10</td>
<td>-0.9%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,196.24</td>
<td>-0.9%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated 12:00 p.m. ET </figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.6% to $579.72.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;inched 0.7% lower to $426.41.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 1% to $491.16.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.7% $219.80.</li>
<li>The Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) outperformed, up 0.6%. The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) lagged, down 1%.</li>
</ul>
<h1 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h1>
<ul>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) fell 2.4% after reporting a worse-than-expected losses<a href="https://www.benzinga.com/news/earnings/24/10/41486950/boeing-q3-earnings-revenue-and-profit-decline-cultural-challenges-ceo-ortberg-vows-transformation"> last quarter</a>.</li>
</ul>
Other stocks reacting to earnings included:
<ul>
<li>Texas Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), up 3.5%.</li>
<li>Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), up 3.9%.</li>
<li>Seagate Technology Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>), down over 7%.</li>
<li>Packaging Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>), up over 6%.</li>
<li>Manhattan Associates Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>), down over 7%.</li>
<li>East West Bancorp. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>), up over 7%.</li>
<li>Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>), down over 13%.</li>
<li>Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), down 2.2%. </li>
<li>Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), down 2.9%.</li>
<li>NextEra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>), down 0.1%. </li>
<li>AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>), up 3.8%. </li>
<li>Boston Scientific Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), down 3.7%. </li>
<li>CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>), down 0.9%. </li>
<li>GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>), down 1.6%. </li>
<li>Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>), down 2.6%. </li>
<li>Vertiv Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>), down 2.8%. </li>
<li>Old Dominion Freight Line Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>), down 4.8%. </li>
</ul>
Large-cap companies reporting earnings after the close include Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), T-Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>), International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>), ServiceNow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), Lam Research Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), United Rentals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>), Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>), Raymond James Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>). 
Read Now:
<ul>
<li><a href="https://www.benzinga.com/markets/bonds/24/10/41455678/gold-on-track-for-best-year-since-1979-veteran-investor-says-sell-bonds-buy-gold">Gold On Track For Best Year Since 1979: Veteran Investor Says &#8216;Sell Bonds, Buy Gold&#8217;</a></li>
</ul>

Equities

Large Cap

Macro Economic Events

Mid Cap

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

ENPH

EWBC

LRCX

MANH

ODFL

TMUS

TSLA

PowerShares DB US Dollar Index Bullish Fund

XLRE

Select Sector SPDR-Consumer Discretionary

Wall Street Slumps For Third Straight Day As Investor Sentiment Fades, Dollar Strength Resumes, Boeing Disappoints: What's Driving Markets Wednesday?

On Wednesday,&nbsp;Thermo Fisher Scientific Inc.&nbsp;(NYSE:&nbsp;TMO) posted third-quarter revenue of $10.59 billion, almost flat year over year, marginally missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $10.64 billion</a>.
Revenue growth, organic revenue growth, and core organic revenue all improved sequentially from Q2 and were flat compared to the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41482387/thermo-fisher-scientific-reports-third-quarter-2024-results" rel="noreferrer noopener">prior-year quarter</a>.
Revenue from the Life Sciences Solutions Segment declined by 1.9% to&nbsp;$2.39 billion. Analytical Instruments Segment sales were up 3.1% to $1.81 billion.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41184148/novo-nordiskastrazenecas-manufacturing-partner-thermo-fisher-questioned-over-manufacturing-lapses" rel="noreferrer noopener">Novo Nordisk/AstraZeneca&#8217;s Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses</a>.
Specialty Diagnostics Segment revenues increased 4.2% to $1.13 billion, and Laboratory Products and Biopharma Services segment sales were almost flat at $5.74 billion.
Adjusted EPS of $5.28 beat the consensus of $5.25 but fell from $5.69 a year ago.&nbsp;
Adjusted operating income for the third quarter of 2024 was $2.36 billion, compared with $2.56 billion in the year-ago quarter. Adjusted operating margin was 22.3%, compared with 24.2% in the third quarter of 2023.
&#8220;We are pleased to deliver strong financial results in the third quarter, reflecting another quarter of sequential improvement in growth,&#8221; said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific.
Casper added, &#8220;Looking ahead, we&#8217;re in a great position to deliver on our 2024 objectives&#8230;&#8221;
Guidance:&nbsp;Thermo Fisher&nbsp;reaffirms its 2024 sales guidance of $42.4 billion—$43.3 billion, compared to the consensus of $42.91 billion.
The life science company revised its adjusted EPS guidance to $21.35-$22.07, compared to its <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39930516/thermo-fisher-q2-earnings-marginal-revenue-dip-completes-olink-acquisition-lifts-annual-profit-outl" rel="noreferrer noopener">previous guidance of $21.29-$22.07</a> and consensus of $21.72.
Price Action: TMO stock traded lower by 2.17% to $573.66 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41127566/industry-leader-thermo-fishers-contract-services-positioned-for-growth-amid-popular" target="_blank" rel="noreferrer noopener">Industry Leader Thermo Fisher&#8217;s Contract Services Positioned For Growth Amid Popular Demand For GLP-1 Weight Loss Drugs, Analyst Initiates With Long-Term Growth Potential</a></li>
</ul>
Photo via Shutterstock

Earnings

Guidance

Health Care

Movers

Thermo Fisher Scientific Sails Through Q3 With Mixed Earnings, CEO Says In Great Position To Deliver 2024 Objectives

Thermo Fisher Reaffirms Its 2024 Revenue Guidance Of $42.4B-$43.3B Versus Consensus Of $42.91B

Thermo Fisher Raises Its 2024 Adjusted EPS Guidance To $21.35-$22.07 Versus Its Previous Guidance Of $21.29-$22.07 And Consensus Of $21.72

Thermo Fisher Scientific Q3 2024 Adj. EPS $5.28 Beats $5.25 Estimate, Sales $10.598B Miss $10.638B Estimate

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) is preparing to release its quarterly earnings on Wednesday, 2024-10-23. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Thermo Fisher Scientific to report an earnings per share (EPS) of $5.25.
The market awaits Thermo Fisher Scientific's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.25, leading to a 3.44% increase in the share price on the subsequent day.
Here's a look at Thermo Fisher Scientific's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>5.12</td>
<td>4.71</td>
<td>5.64</td>
<td>5.61</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>5.37</td>
<td>5.11</td>
<td>5.67</td>
<td>5.69</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729609380_0.png" alt="eps graph" />
<h3>Tracking Thermo Fisher Scientific's Stock Performance</h3>
Shares of Thermo Fisher Scientific were trading at $595.37 as of October 21. Over the last 52-week period, shares are up 36.08%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Views on Thermo Fisher Scientific</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Thermo Fisher Scientific.
The consensus rating for Thermo Fisher Scientific is Outperform, derived from 15 analyst ratings. An average one-year price target of $665.4 implies a potential 11.76% upside.
<h3>Peer Ratings Overview</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Danaher, IQVIA Hldgs and Agilent Technologies, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, Danaher is favoring an Outperform trajectory, with an average 1-year price target of $283.42, suggesting a potential 52.4% downside.</li>
<li>The consensus among analysts is an Outperform trajectory for IQVIA Hldgs, with an average 1-year price target of $268.5, indicating a potential 54.9% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Agilent Technologies, with an average 1-year price target of $148.78, suggesting a potential 75.01% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary offers a detailed examination of key metrics for Danaher, IQVIA Hldgs and Agilent Technologies, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thermo Fisher Scientific</td>
<td>Outperform</td>
<td>-1.37%</td>
<td>$4.35B</td>
<td>3.33%</td>
</tr>
<tr>
<td>Danaher</td>
<td>Outperform</td>
<td>-2.86%</td>
<td>$3.43B</td>
<td>1.76%</td>
</tr>
<tr>
<td>IQVIA Hldgs</td>
<td>Outperform</td>
<td>2.31%</td>
<td>$1.33B</td>
<td>5.56%</td>
</tr>
<tr>
<td>Agilent Technologies</td>
<td>Neutral</td>
<td>-5.62%</td>
<td>$855M</td>
<td>4.65%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Thermo Fisher Scientific ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.
<h3>Get to Know Thermo Fisher Scientific Better</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
<h3>Unraveling the Financial Story of Thermo Fisher Scientific</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Decline in Revenue: Over the 3 months period, Thermo Fisher Scientific faced challenges, resulting in a decline of approximately -1.37% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Thermo Fisher Scientific's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.69% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Thermo Fisher Scientific's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.33%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.58%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.75.
<a href="https://www.benzinga.com/quote/TMO/earnings">To track all earnings releases for Thermo Fisher Scientific visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Thermo Fisher Scientific

JPMorgan's 'Analyst Focus List' – growth, income, value, short ideas

Thermo Fisher Scientific Inc. (TMO) Wolfe 2024 Healthcare Conference (Transcript)

Overweight-rated companies that are focused on 'operational efficiency' – MS

BlackRock Advantage Large Cap Value V.I. Fund Q3 2024 Commentary

BlackRock Unconstrained Equity Fund Q3 2024 Commentary

XLV: Healthcare Stocks In Critical Condition (Rating Downgrade)

Franklin DynaTech Fund Q3 2024 Commentary

Franklin DynaTech SMA Q3 2024 Commentary

Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC

Tracking Al Gore's Generation Investment Management Portfolio - Q3 2024 Update

AAPL

ABBV

AGCO

ALGN

ALHC

ALLY

ALRM

AMAT

AMGN

AMZN

ARMK

ASML

ASND

AVGO

AXON

BALL

BIIB

BRBR

CADE

CBRE

CDNS

CHWY

CLOV

CLVT

CMCSA

COST

CTVA

CVNA

CYBR

DAWN

DELL

DKNG

EWTX

GILD

GOOG

GOOGL

GWRE

HSIC

HTHT

INTC

INTU

ISRG

KLAC

KVUE

LEGN

LVMHF

MELI

MKSI

MNDY

MPWR

MSFT

NTNX

NTRA

NVDA

PODD

RACE

RELY

ROIV

RVMD

SCHW

SIRI

SNDX

SNPS

SNYNF

SOPH

SPGI

SWTX

TFII

TOST

TRGP

TRMB

TSMWF

TVTX

TWLO

TYGO

ULTA

VEEV

VICI

WDAY

XENE

Screenshot 2024-11-21 at 6.41.48 PM

Biotech

Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test

Screenshot 2024-11-12 at 8.43.58 PM

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening

Press Releases

Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements

"Nasdaq Stocks Set for Explosive Growth: BNZI, SEEL, PRSO, MSS, HSCS Revamp for Big Potential"

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 23, 2024

Thermo Fisher Scientific Reports Third Quarter 2024 Results

Thermo Fisher Scientific Declares Quarterly Dividend

Thermo Fisher Scientific to Present at the Wolfe 2024 Healthcare Conference on November 19, 2024

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

Thermo Fisher Scientific Authorizes $4 Billion of Share Repurchases

BATL

BDTX

BNZI

HSCS

KAVL

PRSO

SEEL

Agilent Technologies

AbCellera Biologics

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

Comments

Thermo Fisher Scientific

ニュース

最新ニュース Thermo Fisher Scientific (NYSE:TMO) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル